RO7268489   Click here for help

GtoPdb Ligand ID: 14749

Synonyms: example 27(and 29) [US11802133] | RG-6182 | RO-7268489
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: RO7268489 (RG6182) is a potent, selective, brain-penetrant monoacylglycerol lipase (MAGL) inhibitor. It is one of the claims in Hoffmann La Roche patent US11802133B2 [1]. MAGL inhibition is proposed to increase levels of the endocannabinoid 2-arachidonoylglycerol (2-AG) and decrease pro-inflammatory lipid mediators, as a mechanism to reduce multiple sclerosis-associated neuroinflammation and pain.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 71.11
Molecular weight 431.38
XLogP -0.28
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=C(COC2CN(C2)C(=O)N3CC[C@@]4([H])[C@@]([H])(C3)NC(=O)CO4)C(=CC(=C1)C(F)(F)F)F
Isomeric SMILES [H][C@@]12CCN(C[C@]2(NC(CO1)=O)[H])C(N3CC(OCC4=C(F)C=C(C(F)(F)F)C=C4)C3)=O
InChI InChI=1S/C19H21F4N3O4/c20-14-5-12(19(21,22)23)2-1-11(14)9-29-13-6-26(7-13)18(28)25-4-3-16-15(8-25)24-17(27)10-30-16/h1-2,5,13,15-16H,3-4,6-10H2,(H,24,27)/t15-,16+/m1/s1
InChI Key OMPHREPNGJGUNZ-CVEARBPZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
RO7268489 was progressed as a clinical candidate, as a potential add-on therapy for progressive multiple sclerosis alongside anti-CD20 biologic ocrelizumab.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07282574 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) Phase 2 Interventional Hoffmann-La Roche